Multiple studies have demonstrated that melatonin can mediate the nuclear rejection of the AR in prostate cancer cells without inhibiting the binding capacity of androgens to the AR (Rimler et al., 2001; Rimler et al., 2002) (as shown in Figure 2). The gene discussed is AR; the disease is prostate carcinoma.